Johnson & Johnson
JNJ
$155.75
Share price
-0.72%
Change (1 day)
-4.66%
Change (1 year)
Categories
Johnson & Johnson is a global American pharmaceutical and consumer goods company with headquarters in New Brunswick, New Jersey. The company is listed in the Dow Jones Industrial Average.
Johnson & Johnson (JNJ) - Cash on Hand
Cash on Hand as of March 2023 : $24.61 B
According to Johnson & Johnson's latest financial reports the company has $24.61 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Johnson & Johnson - Cash on Hand chart (from 2001 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2022-12-31 | $23.51 B | -25.59% |
| 2021-12-31 | $31.60 B | 25.5% |
| 2020-12-31 | $25.18 B | 30.58% |
| 2019-12-31 | $19.28 B | -2.03% |
| 2018-12-31 | $19.68 B | 7.6% |
| 2017-12-31 | $18.29 B | -56.34% |
| 2016-12-31 | $41.90 B | 9.2% |
| 2015-12-31 | $38.37 B | 15.98% |
| 2014-12-31 | $33.08 B | 13.3% |
| 2013-12-31 | $29.20 B | 38.49% |
| 2012-12-31 | $21.08 B | -34.63% |
| 2011-12-31 | $32.26 B | 16.64% |
| 2010-12-31 | $27.65 B | 42.38% |
| 2009-12-31 | $19.42 B | 51.65% |
| 2008-12-31 | $12.80 B | 37.51% |
| 2007-12-31 | $9.31 B | 128.09% |
| 2006-12-31 | $4.08 B | -74.69% |
| 2005-12-31 | $16.13 B | 25.26% |
| 2004-12-31 | $12.88 B | 35.29% |
| 2003-12-31 | $9.52 B | 27.4% |
| 2002-12-31 | $7.47 B | -6.23% |
| 2001-12-31 | $7.97 B |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | $11.17 B | -54.60% | 🇨🇭 Switzerland |
 Pfizer PFE | $19.97 B | -18.86% | 🇺🇸 USA |
 Abbott Laboratories ABT | $9.53 B | -61.27% | 🇺🇸 USA |
 Medtronic MDT | $7.95 B | -67.66% | 🇮🇪 Ireland |
 Eli Lilly LLY | $2.82 B | -88.51% | 🇺🇸 USA |
 Sanofi SNY | $8.68 B | -64.71% | 🇫🇷 France |
 Gilead Sciences GILD | $8.00 B | -67.49% | 🇺🇸 USA |
 Stryker Corporation SYK | $1.47 B | -94.00% | 🇺🇸 USA |
 Merck MRK | $10.38 B | -57.80% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $8.20 B | -66.67% | 🇬🇧 UK |